Genentech Plans Avastin Renal Cell Cancer, Breast Cancer sBLA Filings
Executive Summary
Fueled by positive early data, Genentech is in discussions with FDA regarding a potential sBLA submission for Avastin (bevacizumab) for renal cell cancer, the company announced
You may also be interested in...
Avastin Growth Not Limited To Breast Cancer In 2008, Genentech Says
Genentech anticipates continued sales growth for its blockbuster oncologic Avastin regardless of whether it is approved for first-line treatment of metastatic breast cancer
Avastin Growth Not Limited To Breast Cancer In 2008, Genentech Says
Genentech anticipates continued sales growth for its blockbuster oncologic Avastin regardless of whether it is approved for first-line treatment of metastatic breast cancer
Lucentis Faces Additional Pressure From NIH’s Avastin Trials
Genentech could face difficulties enrolling trials for its ocular vascular endothelial growth factor inhibitor Lucentis due to pressure from NIH-sponsored trials of the firm's oncologic VEGF inhibitor Avastin